{"entity":{"id":"nct05862012","kind":"trial","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","aka":[],"tldr":"A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.","summary":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) is a phase 1 interventional study registered as NCT05862012 by Ichnos Sciences SA, with 200 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-07. Interventions recorded: ISB 2001, ISB 2001. Conditions recorded: Relapsed/Refractory Multiple Myeloma.\n\nLinked to the drug ISB 2001 because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05862012","url":"https://clinicaltrials.gov/study/NCT05862012"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["isb-2001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05862012","phase":"1","setting":"A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma","sponsor":"Ichnos Sciences SA","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05862012/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/"}]}}